LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and be...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2018-05-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2717 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and benefits of cardiovascular risk reduction in DM2 with prescription of the antagonist of glucagonlike peptide 1 — liraglutide (Victoza®). |
|---|---|
| ISSN: | 1560-4071 2618-7620 |